Rheumatoid Arthritis is Caused by Asymptomatic Proteus Urinary Tract Infections by Rashid, Taha & Ebringer, Alan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
11 
Rheumatoid Arthritis is Caused by 
Asymptomatic Proteus  
Urinary Tract Infections 
Taha Rashid and Alan Ebringer 
King’s College, Analytical Sciences Group,  
London  
U.K  
1. Introduction 
Urinary tract infections (UTI) are considered as one of the most common groups of 
infections in humans and affecting either the upper (kidneys--pyelonephritis) or the lower 
(bladder--cystitis) part of the urinary tract (Thomson and Armitage, 2010).  
The gastrointestinal tract is a reservoir from which uropathogens emerge. Reflecting this, 
Enterobacteriaceae are the most important cause of UTI in all population groups, accounting 
for more than 95% of all UTIs. Among these microbes, E. coli is by far the most common 
invader, causing some 90% of UTIs in outpatients and approximately 50% in hospitalized 
patients. Whilst, the frequency of P. mirabilis causing outpatient and inpatients UTIs were 
3.2% and 12.7% respectively, these value were reversed to 26.6% and 9.3% when all strains 
of Proteus species were examined (Talkoff-Robin et al, 2008). In a most recent multicentre 
study involving nine Spanish hospitals, 784 women with uncomplicated cystitis were 
evaluated for the frequencies of isolated uropathogens and their susceptibility to antibiotics. 
Among the 650 pathogens isolated, the first group of the most frequent bacterial agents was 
Escherichia coli (79.2%) followed by Staphylococcus saprophyticus (4.4%), Proteus mirabilis 
(4.3%), Enterococcus faecalis (3.3%), and Klebsiella pneumoniae (2.3%) (Palou et al, 2011). 
In contrast to E. coli strains, it appears that all strains of P. mirabilis, regardless of isolate 
origin, are capable of infecting the urinary tract (Sosa et al, 2006). Proteus is particularly 
significant as a renal pathogen especially in causing upper UTI because of its propensity to 
promote struvite renal calculi (Ronald and Nicolle, 2007). 
2. Asymptomatic bacteriuria and subclinical urinary infections 
Bacteriuria might be either symptomatic or asymptomatic. An estimated 40% of women and 
12% of men will experience at least one attack of symptomatic or overt UTI during their 
lifetime, and approximately a quarter of affected women will suffer recurrent UTIs within 6-
12 months (Nielubowicz and Mobley, 2010).  
Asymptomatic bacteriuria (ABU) is considered as one of the most common findings in 
women all over the world. It is defined as the presence of ≥105 cfu/ml of the same bacterial 
species in two consecutive midstream urine samples (Schmiemann et al, 2010). Although in 
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the majority of patients with ABU the site of infection is in the lower urinary tract, some 
individuals with ABU, however, do have upper tract involvement (Ronald and Nicolle, 
2007). In a cross-sectional longitudinal study, Kunin and associates have found that among 
16,000 schoolgirls with ages ranging between 6 to 18 years the prevalence of UTI was 1.2%, 
and two-third of 5% girls who had one or more episodes of bacteriuria were asymptomatic 
(Kunin, 1970). It also appears that the prevalence of asymptomatic bacteriuria increases with 
age and this has been reported by Gaymans et al (1976), where in a study of 1,758 Dutch 
women, the prevalence of bacteriuria was found to be increased from 2.7% of women aged 
15 to 24 years to 9.3% of women aged 65 years or older. 
Although it is usually true to say that bacteriuria is a valid indicator of either bacterial 
localization or infection of the urinary tract, studies in animals (Mulvey et al, 1998) and 
humans (Elliott et al, 1985) have indicated that bacteria may reside in the urothelium in the 
absence of bacteriuria. The majority of patients with kidney or upper tract infection show 
the clinical signs and symptoms of pyelonephritis, but in others this might not be the case. 
In a study by Stamey et al (1965), using ureteral catheterization it was shown that 50 percent 
of women with asymptomatic bacteriuria had infection in their upper tracts, and that a 
small but significant proportion of women with preliminary associated cystitis also had 
upper UTI. It is possible that bacteria within the kidney or upper urinary tract may remain 
latent in a nidus of infection for any length of time (Cattell, 2005). For example Proteus spp. 
can form urinary calculi and remain dormant inside these infected stones undetected and 
resistant to the effects of antibiotics used. It should also be stressed that P. mirabilis is 
probably the second most common microbe among the family of Enterobacteriaceae after E. 
coli in causing UTI, especially of the upper tract in middle-aged and elderly women (Senior, 
1979). 
3. Rheumatoid arthritis and urinary tract infections 
Rheumatoid arthritis (RA) is a potentially disabling chronic systemic polyarthropathy with a 
world-wide distribution and an increased likelihood to have a considerable amount of 
negative impacts on the economical status of the patient and society (Zhang and Anis 2011). 
The cause of this disease is generally agreed to be due to a combined action of genetic and 
environmental (mainly microbial) factors (Firestein, 2009). 
Among the urologists and rheumatologists, the evidence of the link between UTIs and RA is 
not apparently recognized because of the consistent lack of data supporting this association 
and more probably because of the possibility for an existing hidden infection expressed in 
the form of asymptomatic bacteriuria in patients with RA.  
In a preliminary study carried out by a group from Tel Aviv, it has been found that 35 
percent of patients with RA and secondary Sjogren’s syndrome had recurrent attacks of 
UTIs (Tishler et al, 1992). Furthermore, another group from Edinburgh, using a necroscopic 
examination of kidneys from dead patients with RA, found that approximately 17.6 percent 
of males and 22.7 percent of female patients showed signs of chronic pyelonephritis 
(Lawson and Maclean, 1966). A similar result was found in a previous study carried out by a 
group from Copenhagen, where a considerably high degree of associated non-obstructive 
pyelonephritis and renal papillary necrosis was detected among the renal autopsy materials 
from patients with RA (Clausen and Pedersen, 1961). However, this kind of association 
between RA and UTIs was not always observed (Vandenbroucke et al, 1987). This 
discrepancy in the results with an apparent lack of the epidemiological link between urinary 
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infections and RA could be due to the occurrence of sub-clinical or occult infections, which 
are merely characterized by bacteriuria. 
4. Proteus in the urine of patients with RA 
RA is most probably caused or initiated by an upper urinary tract infection with Proteus 
bacteria. Regarding this particular subject, more than 100 articles have been published by 
our and various other collaborative as well as independent groups throughout the world 
(Ebringer et al, 2010). 
The first evidence of a link between Proteus microbe and RA was reported nearly three 
decades ago where in a study by Chandler and co-workers, it was shown that among a 
panel of 30 microbial agents tested, the mean geometric titres of antibodies were raised only 
against Proteus OXK and herpes virus hominis microbes in 22 newly diagnosed RA patients 
when compared to 22 control subjects (Chandler et al, 1971). Meanwhile, this disease-
microbe association was established fourteen years later in a study by our group, where a 
significant elevation of Proteus antibodies (p<0.001) was shown in 30 patients with RA 
compared to 41 healthy controls (Ebringer et al, 1985). To search for the source of this 
microbe in urinary tract of RA patients various studies were carried out by our and other 
independent groups: 
1. In a controlled study of 89 patients with RA from London, P. mirabilis was isolated from 
the urine of 63% of female and 50% of male patients and these results were found to be 
significant in comparison to female (32%) (p<0.001) or male (11%) (p<0.001) healthy 
subjects. However, the frequency of the isolation of Proteus from urine of men and 
women patients without RA (osteoarthritis, fibromyalgia, psoriasis, gout, and systemic 
lupus erythematosus) was 7% and 35% respectively, which were similar to those 
obtained from healthy men (11%) and women (32%) individuals (Figure 1). 
Furthermore, a positive correlation was found between high anti-Proteus antibody 
levels in sera of RA patients and the number of colony-forming units obtained from 
urine specimens of these patients (Wilson et al, 1997). 
2. In another study carried out by a group of scientists from Dundee in the UK, a 
significantly increased isolation rate of Proteus microbes from the urine of 76 patients 
(33%) were detected when compared to those of 48 gender-matched healthy individuals 
(4%) (Senior et al 1999) and this isolation rate was found to be occurring twice more 
frequently as E. coli. In the same study significant elevations (p<0.001) of antibodies 
against P. mirabilis were detected in the urine and serum samples of patients with RA 
when compared to the corresponding healthy subjects.  
Another group, however, was unable to find a significant increase in the isolation of Proteus 
microbes from the urine or faeces of RA patients (McDonagh et al, 1994).  
5. Proteus virulence factors and cross-reactive antigens 
The main virulence factors which have been involved in the uropathogenetic mechanisms 
and utilized by the major group of uropathogens, namely E. coli and P. mirabilis include 
motility, adherence, biofilm formations, β-lactamase productions, toxin productions, 
hydrolytic enzyme productions, metal acquisitions and evasion of the host immune 
defenses (Dobrindt, 2010).  
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Fig. 1. Percentage isolation of Proteus bacteria from the urine of rheumatoid arthritis (RA) 
and non-RA patients and healthy controls. (Urine cultures were measured down to the level 
of 1 cfu/ml of urine, to determine presence or absence of  bacterial signal). 
In contrast to E. coli, P. mirabilis is the main producer of the urease enzyme (Rozaliski et al, 
1997), which hydrolyzes urea into ammonia and carbonate. One of the hallmarks of UTI 
caused by P. mirabilis is the production of urinary stones through action of urease. These 
stones which are a composite of magnesium ammonium phosphate crystals (struvite), might 
act as infective reservoirs of Proteus microbes, and basically protected from host defenses 
and antibiotic treatment (Li et al, 2002).  
Proteus microbes possess various different antigens. Two of these were found to resemble 
self tissue antigens. The Proteus haemolysin protein possesses six amino acid molecules 
“ESRRAL” which resembles a similar amino acid motif “EQRRAA” present in the HLA-
DR1/4 genetic molecules (Wilson et al, 1995) frequently found in association with RA 
(Stastny, 1976). Whilst another group of antigens comprising five amino acid molecules 
“IRRET” which is present in Proteus urease resembles the “LRREI” motif present in type XI 
collagens (Wilson et al, 1995), which is found in hyaline cartilage of the joint tissues. 
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6. Proteus antibodies and their role in the pathogenetic mechanism of RA 
Elevated levels of antibodies to P. mirabilis have been detected in patients with RA among 
many populations from 14 different countries including UK, USA, France, and Netherlands 
(Ebringer et al, 2010). These results have been detected by using various immunological 
methods carried out by collaborative (Table 1) and other independent (Tables 2) groups. The 
specificity of Proteus antibodies in patients with RA was shown in many studies. Deighton et 
al, found that antibodies to P. mirabilis but not to four different viruses (Deighton1 et al, 
1992) were elevated significantly in RA patients. Moreover, in a review analysis it was 
shown that in patients with RA there were significant elevations of antibodies to Proteus but 
not against more than 20 other enterobacterial or uropathogenic microbes, including E. coli 
(Rashid et al, 2007). 
As the result of molecular mimicry or similarity between Proteus and self antigens, patients 
infected with Proteus microbes will produce not only antibodies against this microbe but 
also against the self tissue molecules carrying the cross-reactive antigens. These antibodies 
will bind to and be cytopathic to the joint tissues which carry Proteus cross-reactive antigens 
(Wilson et al, 2003) and this immune reaction will lead to the release of more self tissue 
antigens with a consequent production of further autoantibodies, propagation of the 
pathological process and the development of classical RA, in the same way that Streptococcus 
causes rheumatic fever and valvular lesions in the heart (Guilherme et al, 2011). 
7. A proposal for a new treatment in RA—eradication of Proteus microbes 
Currently the pharmacologic treatment of RA mainly involves the use of disease modifying 
anti-rheumatic drugs and biological agents (Haraoui and Pope, 2011). In concurrent use 
with these medical treatments other therapeutic measures can be employed in order to 
eradicate Proteus bacteria from the urinary tract which could help to prevent further tissue 
and joint damages in patients with RA. These measures could involve the use of cranberry 
juice products, antibiotics or even vaccination.  
Cranberry products have been used widely for several decades for the prevention and 
treatment of UTIs. A meta-analysis has established that recurrence rates of UTIs over 1 year 
are reduced approximately by 35% in young to middle-aged women (Guay, 2009). Other 
studies, however, either supported (Ferrara et al, 2009) or disputed (Barbosa-Cesnik et al, 
2011) the effect of cranberry preparations in the prevention of UTIs. 
Although the use of anti-microbial agents has not been recognized in the management of 
RA, some antibiotics have already been tried with encouraging results. Among these are 
sulphasalazine, metronidazole, rifampicin and minocycline (Ebringer et al, 2003). Some 
problems, however, exist in regard to the use of antibiotics against Proteus microbes. Firstly, 
Proteus infection affects mainly the kidneys and upper urinary tract (Fairley, et al, 1971) 
where the use of ordinary sterilizing substances and antibiotics can be less effective. 
Secondly, P. mirabilis possesses various virulence factors which enhance its urinary 
epithelial invasiveness rendering this microbe resistant to antibiotics (Mathoera et al, 2002). 
Thirdly, when an infected struvite stone is present in the kidney, none of the antibiotic 
agents seems to be effective unless the stone is removed by surgery or shock-wave therapy. 
In order to test the effects of antibiotics in patients with RA through prospective 
longitudinal studies, the search for an effective anti-Proteus chemotherapeutic agent is 
mandatory. In a most recent study from Japan it was shown that all of the P. mirabilis strains 
including extended system β-lactamase (ESBL)-producing strains were susceptible to 
penicillin derivatives combined with β-lactamase inhibitors (Ishikawa et al, 2011). In another 
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study, it was shown that among the three carbapenems tested, meropenem was the most 
potent antibiotic being effective against the majority of the Proteus species isolates (Lee et al, 
2011). If patients with RA respond to anti-microbial measures, prophylaxis of susceptible 
individuals could be instigated by the mean of immunization with attenuated antigens from 
causative microbe or other cross-reactive microbes among the Enterobacteriaceae group 
(Scavone et al, 2011).  
It is logical to start treating patients with RA from early stages of the disease in order to 
prevent further irreversible joint damages from occurring. If such early therapy is 
undertaken the possibility arises that RA may be eradicated in the same way that rheumatic 
fever has been eliminated in the Western World by the means of early treatment of 
Streptoccocal tonsillitis with penicillin and other related antibiotics. 
8. General discussion 
It generally appears that there is an apparent relationship between Proteus asymptomatic 
UTIs and RA. The main hallmark of this association is based on showing the linkage 
between RA and Proteus but not other microbes in the majority of studies carried out by 
various groups throughout the world. The combination of isolation of Proteus microbes in 
the urine and elevation of antibodies in sera of RA patients as well as the evidence for the 
cytopathic effects of these antibodies against the joint tissue cross-reactive antigens, forms 
the major evidence for the role of this microbe in the development of RA. Elimination of 
Proteus microbes by using cranberry juice, antibiotics could have a remarkable effect in the 
management of RA patients alongside currently used anti-rheumatic drugs. It would appear 
that the management of RA may be relevant to urologists as well as to rheumatologists. 
 
YEAR RA HC METHOD P VALUE REFERENCE 
1985 30 41 AM P<0.001 Ebringer et al 
1988 32 18 ELISA P<0.05 Khalafpour et al 
1995 50 49 ELISA P<0.001 Fielder et al 
1995 40 30 ELISA P<0.001 Wilson et al 
1995 34 33 ELISA+IIF P<0.001 Subair et al 
1996 66 60 ELISA P<0.001 Tiwana et al 
1997 50 50 ELISA P<0.001 Tani et al 
1997 89 234 ELISA P<0.001 Wilson et al 
1997 60 60 ELISA P<0.001 Tiwana et al 
1998 25 34 IIF P<0.001 Blankenberg-Sprenkels 
et al 
1999 114 69 IIF P<0.001 Rashid et al 
2003 51 38 ELISA P<0.001 Wilson et al 
2004 159 53 IIF P<0.001 Rashid et al 
2006 50 38 ELISA P<0.0001 Rashid et al 
2007 70 20 ELISA P<0.001 Rashid et al 
RA = rheumatoid arthritis; HC = healthy controls; AM = agglutination method ; ELISA = enzyme-
linked immunosorbent assay; IIF = indirect immunofluorescence. 
Table 1. Studies carried out by various collaborative groups showing increased anti-Proteus 
antibodies in patients with RA compared to HC individuals (number of subjects indicated in 
each study). 
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YEAR RA CONTROLS* METHOD P VALUE REFERENCE 
1988 29 30 ELISA P<0.01 Rogers et al 
1991 9 10+10 (AS+HC) ELISA p<0.01; NS Murphy et al 
1992 142 121 IIF P<0.0001 Deighton2 et al 
1994 87 29 (non-RA) IIF P<0.003 McDonagh et al 
1995  27 27 (non-RA) ELISA; IB P<0.0001 Senior et al 
1996 40 40 ELISA P<0.001 Dybwad et al 
1997 70 82 AM P<0.001 Wanchu et al 
1999 39 51 ELISA p<0.001 Chou et al 
2003 50 25 AM P<0.001 Gautam et al 
2005 59 63 IB P<0.01 Weisbart et al 
2005 246 43+90 
(SpA+UA) 
ELISA P<0.0003; 
p<0.015 
Newkirk et al 
*Controls are always healthy individuals unless otherwise stated; RA = rheumatoid arthritis; AS = 
ankylosing spondylitis; HC = healthy control; SpA = spondyloarthropathy; UA = undifferentiated 
arthritis; ELISA = enzyme-linked immunosorbent assay; IIF = indirect immunofluorescence; AM = 
agglutination method; IB = immunoblot; NS = not significant. 
Table 2. Studies carried out by independent groups showing increased anti-Proteus 
antibodies in patients with RA compared to controls. 
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